 Whitney Goldner
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 20 | 2025 | 338 | 5.280 |
Why?
| | Thyroidectomy | 9 | 2024 | 107 | 1.370 |
Why?
| | Thyroid Nodule | 4 | 2025 | 56 | 1.250 |
Why?
| | Thyroid Gland | 5 | 2024 | 94 | 1.180 |
Why?
| | Pesticides | 5 | 2019 | 62 | 1.150 |
Why?
| | Hypothyroidism | 4 | 2025 | 71 | 0.980 |
Why?
| | Thyroid Diseases | 4 | 2025 | 36 | 0.930 |
Why?
| | Survivorship | 1 | 2024 | 49 | 0.870 |
Why?
| | Adenocarcinoma | 4 | 2023 | 934 | 0.780 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 209 | 0.770 |
Why?
| | Societies, Medical | 5 | 2025 | 816 | 0.770 |
Why?
| | Carcinoma | 3 | 2025 | 237 | 0.740 |
Why?
| | Agriculture | 3 | 2019 | 102 | 0.740 |
Why?
| | Hormone Replacement Therapy | 3 | 2025 | 98 | 0.730 |
Why?
| | Vitamin D | 4 | 2012 | 392 | 0.660 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 682 | 0.660 |
Why?
| | Cancer Survivors | 1 | 2024 | 279 | 0.640 |
Why?
| | Hyperglycemia | 4 | 2021 | 344 | 0.600 |
Why?
| | Hypophosphatasia | 1 | 2018 | 3 | 0.590 |
Why?
| | Occupational Exposure | 4 | 2019 | 342 | 0.570 |
Why?
| | Agricultural Workers' Diseases | 2 | 2018 | 33 | 0.560 |
Why?
| | Alkaline Phosphatase | 1 | 2018 | 148 | 0.550 |
Why?
| | Hypercalcemia | 1 | 2016 | 19 | 0.510 |
Why?
| | Vitamin D Deficiency | 2 | 2008 | 182 | 0.500 |
Why?
| | Paraganglioma | 1 | 2016 | 51 | 0.490 |
Why?
| | Quality of Health Care | 1 | 2020 | 626 | 0.490 |
Why?
| | Multimodal Imaging | 1 | 2016 | 116 | 0.490 |
Why?
| | Neuroendocrine Tumors | 4 | 2021 | 118 | 0.480 |
Why?
| | Choroid Neoplasms | 1 | 2015 | 8 | 0.480 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 664 | 0.480 |
Why?
| | Quality of Life | 2 | 2024 | 2847 | 0.470 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 45 | 0.460 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 81 | 0.460 |
Why?
| | Relaxin | 2 | 2024 | 20 | 0.450 |
Why?
| | Testosterone | 1 | 2018 | 398 | 0.440 |
Why?
| | Thyrotropin | 3 | 2025 | 114 | 0.440 |
Why?
| | Spouses | 2 | 2018 | 105 | 0.430 |
Why?
| | Thyroxine | 2 | 2025 | 62 | 0.430 |
Why?
| | Neoplasms | 5 | 2025 | 2655 | 0.430 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1575 | 0.430 |
Why?
| | Immunoglobulin G | 1 | 2018 | 886 | 0.420 |
Why?
| | Humans | 56 | 2025 | 136899 | 0.420 |
Why?
| | Lymph Nodes | 1 | 2015 | 493 | 0.390 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 158 | 0.370 |
Why?
| | Adrenal Insufficiency | 2 | 2023 | 32 | 0.370 |
Why?
| | Middle Aged | 22 | 2025 | 33118 | 0.350 |
Why?
| | Adult | 24 | 2025 | 37595 | 0.340 |
Why?
| | Thyroid Hormones | 2 | 2020 | 58 | 0.330 |
Why?
| | Gastric Bypass | 2 | 2008 | 118 | 0.310 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1271 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 89 | 0.300 |
Why?
| | Vitamins | 2 | 2010 | 176 | 0.290 |
Why?
| | Medical Oncology | 3 | 2021 | 289 | 0.290 |
Why?
| | Body Weight | 1 | 2012 | 973 | 0.280 |
Why?
| | Obesity, Morbid | 2 | 2008 | 257 | 0.270 |
Why?
| | Iodine Radioisotopes | 3 | 2022 | 145 | 0.250 |
Why?
| | Aged | 11 | 2025 | 23641 | 0.240 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2024 | 251 | 0.230 |
Why?
| | Iowa | 3 | 2018 | 31 | 0.230 |
Why?
| | North Carolina | 3 | 2018 | 105 | 0.220 |
Why?
| | Retrospective Studies | 12 | 2025 | 15514 | 0.220 |
Why?
| | Blood Glucose | 6 | 2021 | 2161 | 0.220 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1282 | 0.220 |
Why?
| | Male | 22 | 2025 | 67308 | 0.220 |
Why?
| | Endocrine System Diseases | 1 | 2024 | 35 | 0.220 |
Why?
| | Monitoring, Ambulatory | 1 | 2004 | 86 | 0.210 |
Why?
| | Insulin Resistance | 2 | 2011 | 1187 | 0.210 |
Why?
| | Menstrual Cycle | 1 | 2004 | 131 | 0.210 |
Why?
| | Hypophysitis | 1 | 2023 | 3 | 0.210 |
Why?
| | Female | 23 | 2025 | 72703 | 0.210 |
Why?
| | Postoperative Care | 3 | 2020 | 258 | 0.210 |
Why?
| | Cholecalciferol | 2 | 2014 | 58 | 0.200 |
Why?
| | Adenoma | 1 | 2025 | 229 | 0.200 |
Why?
| | Iodine | 1 | 2022 | 27 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 218 | 0.190 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2022 | 35 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2002 | 62 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2490 | 0.190 |
Why?
| | Urticaria | 2 | 2014 | 38 | 0.190 |
Why?
| | Asthenia | 1 | 2021 | 3 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 392 | 0.180 |
Why?
| | Insulin | 2 | 2011 | 2389 | 0.180 |
Why?
| | Prospective Studies | 7 | 2021 | 7543 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 190 | 0.170 |
Why?
| | United States | 6 | 2025 | 14595 | 0.170 |
Why?
| | Radiation-Protective Agents | 1 | 2019 | 26 | 0.160 |
Why?
| | Metalloporphyrins | 1 | 2019 | 103 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 258 | 0.150 |
Why?
| | Hyperthyroidism | 1 | 2019 | 22 | 0.150 |
Why?
| | Lutein | 1 | 2019 | 14 | 0.150 |
Why?
| | Zeaxanthins | 1 | 2019 | 18 | 0.150 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 178 | 0.150 |
Why?
| | Chromatography, Liquid | 2 | 2018 | 433 | 0.150 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 401 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 398 | 0.150 |
Why?
| | Radioimmunoassay | 1 | 2018 | 174 | 0.140 |
Why?
| | Capital Financing | 1 | 2017 | 7 | 0.140 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1240 | 0.140 |
Why?
| | Training Support | 1 | 2017 | 31 | 0.140 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 398 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 116 | 0.130 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2019 | 175 | 0.130 |
Why?
| | Mutation | 2 | 2019 | 3948 | 0.130 |
Why?
| | Age Factors | 1 | 2024 | 3290 | 0.130 |
Why?
| | Succinate Dehydrogenase | 1 | 2016 | 49 | 0.130 |
Why?
| | Fetal Blood | 1 | 2019 | 327 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.130 |
Why?
| | Melanoma | 1 | 2023 | 757 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5126 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 258 | 0.120 |
Why?
| | Transplantation | 1 | 2015 | 34 | 0.120 |
Why?
| | Risk Assessment | 1 | 2024 | 3432 | 0.110 |
Why?
| | Universities | 1 | 2017 | 431 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2018 | 741 | 0.110 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1033 | 0.110 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 3396 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 986 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1057 | 0.110 |
Why?
| | Sepsis | 1 | 2020 | 610 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 658 | 0.110 |
Why?
| | DNA Adducts | 1 | 2013 | 16 | 0.110 |
Why?
| | Cholestanetriol 26-Monooxygenase | 1 | 2012 | 8 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 476 | 0.100 |
Why?
| | Steroid Hydroxylases | 1 | 2012 | 22 | 0.100 |
Why?
| | Obesity | 2 | 2004 | 2966 | 0.100 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2012 | 15 | 0.100 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2012 | 12 | 0.100 |
Why?
| | Pilot Projects | 2 | 2008 | 1684 | 0.100 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 17 | 0.100 |
Why?
| | TATA-Box Binding Protein | 1 | 2012 | 20 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2021 | 2627 | 0.100 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2024 | 221 | 0.100 |
Why?
| | Calcitriol | 1 | 2012 | 58 | 0.100 |
Why?
| | Prevalence | 2 | 2010 | 2709 | 0.090 |
Why?
| | Triiodothyronine | 1 | 2011 | 43 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 285 | 0.090 |
Why?
| | Signal Transduction | 1 | 2024 | 5077 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2021 | 2508 | 0.090 |
Why?
| | Diet | 1 | 2019 | 1261 | 0.090 |
Why?
| | Estrogens | 1 | 2013 | 358 | 0.080 |
Why?
| | Environmental Exposure | 2 | 2018 | 571 | 0.080 |
Why?
| | Fumigation | 1 | 2010 | 3 | 0.080 |
Why?
| | Fungicides, Industrial | 1 | 2010 | 7 | 0.080 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2010 | 81 | 0.080 |
Why?
| | Herbicides | 1 | 2010 | 27 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2014 | 560 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2014 | 442 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 5730 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2018 | 10768 | 0.070 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2008 | 12 | 0.070 |
Why?
| | Parathyroid Hormone | 1 | 2008 | 108 | 0.070 |
Why?
| | Depressive Disorder, Major | 1 | 2011 | 361 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2004 | 3697 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2066 | 0.070 |
Why?
| | Internship and Residency | 1 | 2017 | 1131 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1376 | 0.070 |
Why?
| | Disease Management | 2 | 2025 | 624 | 0.070 |
Why?
| | Dermatitis, Atopic | 1 | 2010 | 325 | 0.070 |
Why?
| | Creatinine | 1 | 2008 | 500 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1400 | 0.060 |
Why?
| | Hospitalization | 1 | 2015 | 2183 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2471 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2024 | 68 | 0.060 |
Why?
| | Receptors, Peptide | 1 | 2024 | 17 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 2060 | 0.060 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2024 | 62 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5398 | 0.050 |
Why?
| | Inpatients | 2 | 2021 | 497 | 0.050 |
Why?
| | Weight Loss | 1 | 2008 | 765 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2783 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 379 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2002 | 27 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3710 | 0.050 |
Why?
| | Gastroplasty | 1 | 2002 | 31 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 99 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 143 | 0.050 |
Why?
| | Thyroglobulin | 1 | 2022 | 27 | 0.050 |
Why?
| | Calcium | 1 | 2008 | 1233 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2004 | 409 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2022 | 39 | 0.050 |
Why?
| | Antigens, CD | 1 | 2024 | 524 | 0.040 |
Why?
| | Risk Factors | 4 | 2019 | 10313 | 0.040 |
Why?
| | Ultrasonography | 1 | 2025 | 749 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2615 | 0.040 |
Why?
| | Thyroiditis | 1 | 2020 | 4 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2025 | 1484 | 0.040 |
Why?
| | Radiography | 1 | 2002 | 834 | 0.040 |
Why?
| | Salivary Glands | 1 | 2019 | 33 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1945 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 790 | 0.040 |
Why?
| | Beta-Cryptoxanthin | 1 | 2019 | 1 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 344 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2030 | 0.040 |
Why?
| | beta Carotene | 1 | 2019 | 22 | 0.040 |
Why?
| | Xanthophylls | 1 | 2019 | 18 | 0.040 |
Why?
| | Carotenoids | 1 | 2019 | 43 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 39 | 0.040 |
Why?
| | Diet Surveys | 1 | 2019 | 95 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2023 | 596 | 0.040 |
Why?
| | Immunotherapy | 1 | 2023 | 645 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 225 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 13157 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1773 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1262 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2021 | 629 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 693 | 0.030 |
Why?
| | Cetirizine | 1 | 2014 | 2 | 0.030 |
Why?
| | Ranitidine | 1 | 2014 | 14 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 89 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1037 | 0.030 |
Why?
| | Acetates | 1 | 2014 | 100 | 0.030 |
Why?
| | Sulfides | 1 | 2014 | 99 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 176 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 919 | 0.020 |
Why?
| | Placenta | 1 | 2019 | 749 | 0.020 |
Why?
| | Medicare | 1 | 2017 | 745 | 0.020 |
Why?
| | Cathelicidins | 1 | 2010 | 41 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 533 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4011 | 0.020 |
Why?
| | Animals | 2 | 2024 | 36915 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5711 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1689 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 252 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5766 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 811 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6043 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2744 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 6715 | 0.020 |
Why?
| | Adolescent | 1 | 2004 | 21402 | 0.010 |
Why?
| | Glyburide | 1 | 2004 | 32 | 0.010 |
Why?
| | Leptin | 1 | 2004 | 233 | 0.010 |
Why?
| | Adiponectin | 1 | 2004 | 241 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2004 | 561 | 0.010 |
Why?
| | Linear Models | 1 | 2004 | 850 | 0.010 |
Why?
| | Metformin | 1 | 2004 | 327 | 0.010 |
Why?
| | Body Composition | 1 | 2004 | 665 | 0.010 |
Why?
| | Lipids | 1 | 2004 | 664 | 0.010 |
Why?
| | Sex Factors | 1 | 2004 | 2067 | 0.010 |
Why?
|
|
Goldner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|